Combination phentermine/topiramate for obesity treatment in primary care: a review.

Glen Xiong, Kishore M. Gadde

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The treatment of obesity is often met with a myriad of challenges in the primary care setting. Nevertheless, a modest 5% weight loss is considered clinically significant and may be associated with health benefits. Phentermine/topiramate (Qsymia), available in the United States since September 2012, achieves clinically meaningful weight loss along with improvements in weight-related comorbidities. This combination drug therapy could be an additional tool for primary care providers in their quest for effective management of obesity. Special precautions and close monitoring are indicated when prescribing phentermine/topiramate for women of childbearing potential. Monitoring of heart rate and psychiatric and cognitive side effects is important.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalPostgraduate Medicine
Volume126
Issue number2
DOIs
StatePublished - 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Combination phentermine/topiramate for obesity treatment in primary care: a review.'. Together they form a unique fingerprint.

  • Cite this